To raise awareness about the advances in the development of new treatments and the importance of clinical trials for patients
Download the free guide
Boost your gains
Paris and Boston, may 10, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in immunotherapy active for the treatment of autoimmune diseases, and Lupus Europe, an association that currently includes 24 organizations of patients national from 22 european countries, uniting their voices on the occasion of the world day of lupus, in order to raise awareness among the general public but also the decision makers on this chronic autoimmune disease and catastrophic, of which the etiology remains poorly known.
Lupus can affect many organs and tissues, the disease is manifested by clinical signs heterogeneous (rashes, arthritis, photosensitivity, renal impairment, neurological disorders, anemia…), which vary from person to person and change over the course of the evolution of the disease, with alternating flare-ups and periods without symptoms (remission). Lupus primarily affects women – 9 women to 1 man. In Europe, around 500 000 people are affected to varying degrees of the disease.1
Fortunately, they can rely on the associations of patients to accompany them. Lupus Europe unites these organisations in order to provide more effective support for people living with lupus across Europe, helping them to understand their illness and improve research and scientific knowledge of the pathology.
Neovacs, a major player in the immunotherapy active is specialized in the development and the development of therapeutic vaccines for the treatment of autoimmune diseases such as lupus. Unlike the monoclonal antibodies from which many of the treatments of cancer and inflammatory diseases are designed, therapeutic vaccines Kinoid® developed by Neovacs allow the production of polyclonal antibodies by the immune system of the patient. Recent work has highlighted the major role of IFNa in the
dysfunction of the immune system of sle patients, opening new perspectives for the treatment of lupus. The IFNa Kinoid is now the most advanced product of the research and development of Neovacs. This therapeutic vaccine, currently in phase IIb for the indication of lupus, is the bearer of hope for the patients whose participation in clinical trials remains essential to help researchers discover new treatments.
“There are 50 years of age, be diagnosed with lupus meant a death sentence. Today, patients can live an almost normal, thanks to the treatments not yet numerous enough and to a better understanding of the disease. What are the clinical trials that are essential for the lupus. Concerning research, we are putting a lot of hope in several labs which has been working for a few years to lupus. We are watching with great interest the possibility of a vaccine, which would be wonderful for patients ! “, explains Anne Charlet, vice-president of the association of Lupus Europe.
1 Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009; 18: 869-74. Carter EA, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nature reviews. Rheumatology 2016: 12(10): 605-620.
About Neovacs
Listed on Alternext Paris since 2010, Neovacs has become a major player in the therapeutic vaccines targeting the treatment of auto-immune diseases and/or inflammatory. Thanks to its innovative technology inducing an immune response, polyclonal, protected potentially until 2032 by 5 families of patents, Neovacs is focusing its development efforts clinic on IFNa-Kinoid for the treatment of lupus and dermatomyositis. Neovacs has also been performing preclinical work on other therapeutic vaccines for the treatment of autoimmune diseases, cancers, allergies and type 1 diabetes. The ambition of this approach “Kinoid” is to allow patients to better endure a life-long treatment, which would be more effective, well-tolerated and very flexible in its administration. Neovacs is eligible for the plan (PEA-PME.
For more information : http://neovacs.fr/
About Lupus Europe
LUPUS EUROPE is an association that currently includes 24 national organizations of patients with sle, coming from 22 member countries across Europe. It is a charitable organization that supports sle patients throughout Europe, keeping its member countries informed by blog, Facebook, Twitter and flash news on a regular basis the work of LUPUS EUROPE in the promotion of lupus at conventions and meetings across Europe.
Its mission is to :
– Make known the lupus across Europe and to ensure standards of high-quality treatment and security, in partnership with physicians, as well as support the sle patients, their family and their support of care.
– Encourage and support the health and social care systems of member countries, to allow the sle patients to live more independently and to be recognized as full-fledged members of the society.
http://lupus-europe.eu/
Download the free guide
Boost your gains
